Prot #MK‐7684A‐010‐02: A Phase 3, Randomized, Double‐blind, Active‐Comparator‐Controlled Clinical Study of Adjuvant MK‐7684A (Vibostolimab with Pembrolizumab) Versus Adjuvant Pembrolizumab in Participants with High‐risk Stage II‐IV Melanoma (KEYVIBE‐010